MSU
KERX

Mizuho Securities USA’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Mizuho Securities USA’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-153,400
Closed -$6K – 219
2017
Q4 		$6K Buy
+153,400
New +$845K ﹤0.01% 170

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mizuho Securities USA's KERX Position: Q2 2018 in Review

Mizuho Securities USA sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2018, closing a stake of 203,400 shares — an estimated $832K sold.

Mizuho Securities USA first reported a position in KERX in Q1 2015 and held it in 8 quarters. The position peaked at $1.81M in Q2 2015. 132 funds tracked by Wall St. Rank hold KERX as of Q2 2018.

  • Mizuho Securities USA reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • Mizuho Securities USA sold 203,400 Keryx Biopharmaceuticals Inc shares in Q2 2018, an estimated $832K.
  • Mizuho Securities USA first reported a position in Keryx Biopharmaceuticals Inc in Q1 2015 and held it in 8 quarters.
  • Mizuho Securities USA's Keryx Biopharmaceuticals Inc position peaked at $1.81M in Q2 2015.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2018.

Based on Mizuho Securities USA's 13F filing for Q2 2018, filed 23 Jul 2018.